Tirzepatide/Semaglutide Weight Loss Intervention in Patients With Endometrial Cancer and Obesity
Bose S, Presswala L (Memorial Sloan Kettering Cancer Center)
Summary
Memorial Sloan Kettering is conducting a pilot study evaluating tirzepatide (with semaglutide as alternative) for weight management in stage I-III endometrial cancer patients with obesity undergoing chemotherapy. The trial will assess feasibility, safety, and preliminary efficacy of combining GLP-1/GIP agonist therapy with curative-intent chemotherapy.
Clinical Significance
This trial represents the growing frontier of GLP-1 RA use in oncology — addressing obesity as a modifiable risk factor during cancer treatment. If successful, it could establish a paradigm for integrating peptide-based weight loss therapy into cancer care protocols.
Trial Details
- Phase: Early Phase 1
- Design: Single-arm pilot study
- Population: Stage I-III endometrial cancer with BMI ≥27 (with comorbidity) or BMI ≥30
- Intervention: SC tirzepatide 2.5mg weekly × 4 weeks → 5mg weekly
- Alternative: Semaglutide 0.25mg weekly if insurance doesn't cover tirzepatide
- Primary endpoint: Treatment completion rate (≥70% of 24 weekly doses)
- Sites: Memorial Sloan Kettering (7 locations, NY/NJ)
- Status: Actively recruiting as of March 2026
Clinical Implications
Combining GLP-1/GIP agonists with chemotherapy could improve cancer outcomes by addressing obesity-related treatment complications. Endometrial cancer has one of the strongest obesity-cancer links, making this a high-priority investigation.
Relateret forskning
Real-World Weight-Loss Outcomes in Weight-Reduced Patients Treated With Tirzepatide
This real-world study of 293 patients found that tirzepatide produced 10.3% total body weight loss i…
Glucagon-like Peptide-1 Receptor Agonists and Risk of Depression: A Systematic Review and Meta-Analysis
This comprehensive meta-analysis examined the relationship between GLP-1 receptor agonist use and de…
Pilot Weight Loss Intervention With Dual GIP/GLP-1 Receptor Agonist Therapy in Patients With Endometrial Cancer and Obesity
Memorial Sloan Kettering is conducting a pilot study evaluating weekly subcutaneous tirzepatide (2.5…
Exposure-Adjusted Safety and Efficacy of GLP-1 and GLP-1/GIP Receptor Agonists for Weight Management and Type 2 Diabetes
This comprehensive analysis of FDA regulatory data across 14 medications and over 34,000 safety subj…